deltatrials
Completed PHASE1 NCT00106769

Vaccine to Prevent West Nile Virus Disease

A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA017-00 VP, in Healthy Adult Volunteers

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions HV Healthy Healthy Volunteer West Nile Fever
Interventions VRC-WNVDNA017-00-VP
Updated 5 times since 2017 Last updated: Jun 30, 2017 Started: Mar 22, 2005 Completion: Jan 15, 2008

Listed as NCT00106769, this PHASE1 trial focuses on HV and Healthy and remains completed. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States